A significant federal advisory board, appointed by Health Secretary Robert F. Kennedy Jr., engaged in two days of intense discussions about potential updates to the CDC’s vaccination policies. However, many of the more contentious suggestions were left unresolved.
During the meeting, the Advisory Committee on Vaccination Practices (ACIP) opted against endorsing a combination vaccine for measles, mumps, rubella, and chickenpox (MMRV) for children under four—a reversal of existing guidelines.
After lengthy, at times confusing, debates, the committee also chose not to vote on a proposed adjustment to the hepatitis B vaccine for newborns.
They did, however, reach a unanimous agreement on stricter guidelines regarding the Covid-19 vaccine, although the implications of this decision remain somewhat unclear.
ACIP’s recommendations carry significant weight; most private insurers are required to cover vaccinations endorsed by this committee, and state vaccination policies often depend on these guidelines.
There’s an important takeaway.
Changes in Childhood Vaccination Schedules
As the panel reexamined the childhood vaccine schedule—having been newly constituted after Kennedy dismissed the previous committee back in June—they voted 8-3 against the current use of the combined MMRV vaccine, which is administered to about 15% of children in the country, increasing the risk of fever-related complications.
Instead of recommending the combination vaccine, they suggested two separate shots, one for MMR and another for chickenpox.
Despite the relatively low uptake for this particular vaccine, some members representing medical professionals expressed concerns about a lack of new evidence to justify these changes and urged the committee not to proceed.
ACIP member Cody Meissner, a pediatrics professor at Dartmouth, voted against the modification. He noted that febrile seizures occur in 3-5% of children, which is alarming but not considered indicative of any disorder. He also argued that the recommendation undermines parental choice.
However, the MMRV discussion is unlikely to be the last word on pediatric vaccines, as the committee is forming a working group focused on childhood and adolescent immunizations.
Hepatitis B Vote Delayed
Perhaps the most unexpected development was the committee’s decision to postpone voting on changes to the hepatitis B vaccination schedule, citing a lack of readiness and confusion over its presentation and proposed language.
Although the vote was initially scheduled for Thursday, it was moved to Friday at the last moment due to inconsistencies in the language. On Friday, members ultimately voted to table the matter indefinitely.
Throughout the discussions, questions arose concerning vaccine safety, and some panelists felt hesitant to make changes without a clear rationale. “I think we’re in a gray area here, and the ongoing debates about safety and efficacy make today’s vote feel a bit rushed,” commented panel member Robert Malone.
“Being cautious tends to yield better results,” added Joseph Hibel, a former psychiatrist and neuroscientist.
The decision received applause from experts in infectious diseases as well as Senator Bill Cassidy (R-La.), who had raised alarms about the potential dangers of reinstating a long-standing policy to vaccinate all newborns against hepatitis B.
“President Trump and I are on the same page: Vaccines save lives. If a mother wishes to obtain a vital hepatitis B vaccine for her newborn, she should have that choice,” Cassidy stated. “The proposed ACIP shift might hinder access, complicating efforts to shield children from hepatitis B.
Experiential Gaps and Confusion
The choice to indefinitely postpone votes highlighted a lack of experience and considerable disarray regarding the voting protocol. About half the committee members had recently been appointed earlier that week.
Additionally, the panel re-evaluated whether the MMRV vaccines should be included under the Vaccine for Children (VFC) program during the discussions on Friday.
Initially, they supported the inclusion, but the phrasing created confusion for some committee members, leading one individual to abstain from voting.
The group ultimately revisited their previous day’s vote.
Community Concerns
The votes held on Friday heightened uncertainty about who can access Covid-19 vaccination. The panel recommended that individuals consult with their healthcare providers about receiving a Covid-19 shot but stopped short of issuing a universal recommendation.
This shift marks a move away from prior universal protocols, and the actual consequences of the decision remain unclear. It could affect insurance coverage for the vaccine, pending sign-off by a federal health authority.
There may also be complications for Americans seeking vaccinations at pharmacies without prescriptions based on state regulations.
CDC data released on Friday indicated that roughly two-thirds of adults who were vaccinated against Covid last year did so at pharmacies.
Reactions to the panel’s decisions were varied.
For instance, AARP expressed discontent over the departure from universal recommendations, stating, “If someone needs a vaccine, access should be assured. We’re worried the CDC’s advisory panel’s stance could hinder older Americans from acquiring the proven Covid-19 vaccine.”
Senator Patty Murray (D-Wash.) criticized the committee’s actions, stating, “This ACIP decision is incredibly troubling. The new restrictions on Covid vaccine access appear to favor unqualified skeptics rather than being grounded in science. One ACIP member insists this is about ‘individual choices,’ but the reality is, many Americans desiring a Covid vaccine might find it out of reach.”
Sanofi, which markets non-mRNA Covid vaccines developed by Novavax, expressed support for the committee’s push to recommend a Covid vaccine.
Future Modifications Ahead
Future modifications seem likely as Friday’s talks about Covid included unverified claims linking vaccines to contamination, cancer, and birth defects.
Hundreds of millions in the US have received Covid-19 vaccines, with billions vaccinated globally, and there’s no substantiated evidence supporting these assertions.
Yet, Tracy Beth Whaeg, a senior adviser with the FDA, did not openly refute the claims, instead emphasizing the agency’s commitment to public safety.
Pfizer representatives informed the committee about a study revealing potential birth defects in women vaccinated later in their pregnancies.
Traditionally, vaccine manufacturers are permitted only a brief speaking opportunity during ACIP meetings. Pfizer mentioned that their vaccine saved between 5,000 and 7,000 lives last year.
Panelist Retsef Levi, who oversees the Coronavirus Vaccine Workgroup, accused the CDC of failing to communicate risks effectively regarding the vaccine; he has expressed skepticism specifically towards mRNA vaccines and has advocated for their removal from the market.
